Market Research Reports and Industry Reports

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H2 2017

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H2 2017, provides an overview of the Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) pipeline landscape.

HIV is a virus which attacks the immune system, and weakens ability to fight infections and disease. Symptoms include fever, sore throat, body rash, joint pain, muscle pain and swollen glands. The most common ways HIV is spread are by having vaginal or anal intercourse without a condom with someone who has HIV/AIDS, sharing needles or syringes with someone who has HIV/AIDS, being deeply punctured with a needle or surgical instrument contaminated with HIV and getting HIV-infected blood, semen, or vaginal secretions into open wounds or sores.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Human Immunodeficiency Virus (HIV) Infections (AIDS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 1, 15, 46, 42, 1, 4, 104, 66 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 2, 16, 20, 55 and 62 molecules, respectively.

Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Human Immunodeficiency Virus (HIV) Infections (AIDS) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 8
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Overview 9
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Therapeutics Development 10
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Therapeutics Assessment 50
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Companies Involved in Therapeutics Development 68
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Drug Profiles 127
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Dormant Projects 893
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Discontinued Products 922
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Product Development Milestones 926
Appendix 938

List Of Tables


Number of Products under Development for Human Immunodeficiency Virus (HIV) Infections (AIDS), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..8), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..4), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Products under Development by Companies, H2 2017 (Contd..5), H2 2017
Products under Development by Companies, H2 2017 (Contd..6), H2 2017
Products under Development by Companies, H2 2017 (Contd..7), H2 2017
Products under Development by Companies, H2 2017 (Contd..8), H2 2017
Products under Development by Companies, H2 2017 (Contd..9), H2 2017
Products under Development by Companies, H2 2017 (Contd..10), H2 2017
Products under Development by Companies, H2 2017 (Contd..11), H2 2017
Products under Development by Companies, H2 2017 (Contd..12), H2 2017
Products under Development by Companies, H2 2017 (Contd..13), H2 2017
Products under Development by Companies, H2 2017 (Contd..14), H2 2017
Products under Development by Universities/Institutes, H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..4), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..5), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..6), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..7), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..5), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Number of Products by Stage and Molecule Type, H2 2017 (Contd..1), H2 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by AbbVie Inc, H2 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Abivax SA, H2 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by AdAlta Ltd, H2 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Advanced Genetic Systems Inc, H2 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Akshaya Bio Inc, H2 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Altor BioScience Corp, H2 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Altravax Inc, H2 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Amarna Therapeutics BV, H2 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by American Gene Technologies International Inc, H2 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Amunix Operating Inc, H2 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Antigen Express Inc, H2 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Aphios Corp, H2 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Apotex Inc, H2 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Argos Therapeutics Inc, H2 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by B Cell Design SAS, H2 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Biological Mimetics Inc, H2 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Bionor Pharma AS, H2 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Biotron Ltd, H2 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Bolder Biotechnology Inc, H2 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Bristol-Myers Squibb Co, H2 2017
Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline by Bukwang Pharm Co Ltd, H2 2017

List Of Figures


Number of Products under Development for Human Immunodeficiency Virus (HIV) Infections (AIDS), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

United States Demineralized Human Bone Allograft Market Report 2017

In this report, the United States Demineralized Human Bone Allograft market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end

USD 3800View Report

Global Human Endostatin Market Professional Survey Report 2017

This report studies Human Endostatin in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from

USD 3500View Report

EMEA (Europe, Middle East and Africa) Human Immunodeficiency Virus (HIV) Rapid Test Kits Market Report 2017

In this report, the EMEA Human Immunodeficiency Virus (HIV) Rapid Test Kits market is valued at USD XX million in 2016 and is expected to reach USD XX million by

USD 4000View Report

Global Human Immunodeficiency Virus (HIV) Rapid Test Kits Market Professional Survey Report 2017

This report studies Human Immunodeficiency Virus (HIV) Rapid Test Kits in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and

USD 3500View Report

Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 2500
  • Site Licence    USD 5000
  • Enterprise Wide Licence    USD 7500
$ 2500

Reports Details

Published Date : Dec 2017
No. of Pages :980
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube